Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.76 |
| ▸ | ABL1 | P00519 | 5/20 | 0.76 |
| ▸ | BRAF | P15056 | 5/20 | 0.76 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.76 |
| ▸ | BTK | Q06187 | 4/20 | 0.76 |
| ▸ | RAF1 | P04049 | 4/20 | 0.76 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.76 |
| ▸ | SRC | P12931 | 3/20 | 0.76 |
| ▸ | TYK2 | P29597 | 3/20 | 0.76 |
| ▸ | SYK | P43405 | 3/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.76 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.76 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.76 |
| ▸ | BCR | P11274 | 3/20 | 0.76 |
| ▸ | KDR | P35968 | 3/20 | 0.76 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 0.76 |
| ▸ | NBAS | A2RRP1 | 2/20 | 0.76 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700123 | 0.94 | ABL1 (0.77) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL4917606 | 0.91 | ABL1 (0.76) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL4699947 | 0.90 | ABL1 (0.83) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL4922941 | 0.88 | ABL1 (0.80) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL4916509 | 0.87 | ABL1 (0.78) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL29380618 | 0.87 | ABL1 (1.00) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL4699731 | 0.87 | ABL1 (1.00) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL29358745 | 0.87 | ABL1 (1.00) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL4820277 | 0.83 | BRAF (0.60) | LCKABL1BRAFDDR2BTK | |
| SCHEMBL18804561 | 0.82 | DDR1 (0.81) | LCKABL1BRAFDDR2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | claimed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | LCK 35/4885ABL1 30/4885BRAF 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.